The Yersinia Phage X1 Administered Orally Efficiently Protects a Murine Chronic Enteritis Model Against Yersinia enterocolitica Infection

Xue, Yunfeng; Zhai, Shengjie; Wang, Zijing; Ji, Yalu; Wang, Gang; Wang, Tianqi; Wang, Xinwu; Xi, Hengyu; Cai, Ruopeng; Zhao, Rihong; Zhang, Hao; Bi, Lanting; Yuan, Guohui; Guo, Zhimin; Wang, Han; Gu, Jingmin

doi:10.3389/fmicb.2020.00351

Cited by 21 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TNF-α, IL-1β, and IFN-γ expressions in the blood exhibited significantly lower levels at 18 h compared with the control groups. The phenomenon is similar to the cytokine secretion of phage X1 (Xue et al, 2020) and phage VB-SavM-JYL01 (Ji et al, 2019) in the treatment of Yersinia and S. aureus. Some studies have shown that phages have anti-inflammatory properties that reduce the secretion of pro-inflammatory factors.…”

Section: Discussionsupporting

confidence: 54%

Genomic, Morphological and Functional Characterization of Virulent Bacteriophage IME-JL8 Targeting Citrobacter freundii

et al. 2020

Self Cite

View full text Add to dashboard Cite

Citrobacter freundii refers to a fish pathogen extensively reported to be able to cause injury and high mortality. Phage therapy is considered a process to alternatively control bacterial infections and contaminations. In the present study, the isolation of a virulent bacteriophage IME-JL8 isolated from sewage was presented, and such bacteriophage was characterized to be able to infect Citrobacter freundii specifically. Phage IME-JL8 has been classified as the member of the Siphoviridae family, which exhibits the latent period of 30–40 min. The pH and thermal stability of phage IME-JL8 demonstrated that this bacteriophage achieved a pH range of 4–10 as well as a temperature range of 4, 25, and 37°C. As revealed from the results of whole genomic sequence analysis, IME-JL8 covers a double-stranded genome of 49,838 bp (exhibiting 47.96% G+C content), with 80 putative coding sequences contained. No bacterial virulence- or lysogenesis-related ORF was identified in the IME-JL8 genome, so it could be applicable to phage therapy. As indicated by the in vitro experiments, phage IME-JL8 is capable of effectively removing bacteria (the colony count decreased by 6.8 log units at 20 min), and biofilm can be formed in 24 h. According to the in vivo experiments, administrating IME-JL8 (1 × 107 PFU) was demonstrated to effectively protect the fish exhibiting a double median lethal dose (2 × 109 CFU/carp). Moreover, the phage treatment led to the decline of pro-inflammatory cytokines in carp with lethal infections. IME-JL8 was reported to induce efficient lysis of Citrobacter freundii both in vitro and in vivo, thereby demonstrating its potential as an alternative treatment strategy for infections attributed to Citrobacter freundii.

show abstract

Section: Discussionsupporting

confidence: 54%

Genomic, Morphological and Functional Characterization of Virulent Bacteriophage IME-JL8 Targeting Citrobacter freundii

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, the number of Y. enterocolitica in mice colon and caecum tissues was reduced to approximately 10 3 CFU/g after 18 h compared with 10 7 CFU/g in the mice without phage treatment. These results indicate that phage X1 is a promising candidate to control infection by Y. enterocolitica in vivo (Xue et al 2020).…”

Section: Genus Yersiniamentioning

confidence: 76%

“…Preliminary research on this group of phages was conducted in the second half of the twentieth century and was based on phage typing and electron microscopy observations. Further reports focussed on more specific data including morphology of phage particles, the host range, genome sequence, and identification of the receptors involved in host recognition (Leon-Velarde et al 2019;Xue et al 2020) Application of Y. enterocolitica specific phages, especially as part of phage therapy, has rarely been reported. Xue et al (2020) discovered the new Yersinia enterocolitica specific phage X1, which may be considered a possible agent for phage therapy.…”

Section: Genus Yersiniamentioning

confidence: 99%

“…Further reports focussed on more specific data including morphology of phage particles, the host range, genome sequence, and identification of the receptors involved in host recognition (Leon-Velarde et al 2019;Xue et al 2020) Application of Y. enterocolitica specific phages, especially as part of phage therapy, has rarely been reported. Xue et al (2020) discovered the new Yersinia enterocolitica specific phage X1, which may be considered a possible agent for phage therapy. This virus can cross the stomach barrier and efficiently reach the intestine in vivo without losing infectious ability.…”

Section: Genus Yersiniamentioning

confidence: 99%

See 1 more Smart Citation

Applications of bacteriophages against intracellular bacteria

Śliwka

Ochocka

Skaradzińska

2021

Critical Reviews in Microbiology

View full text Add to dashboard Cite

Infectious diseases pose a significant threat to both human and animal populations. Intracellular bacteria are a group of pathogens that invade and survive within the interior of eukaryotic cells, which in turn protect them from antibacterial drugs and the host immune system. Limited penetration of antibacterials into host cells results in insufficient bacterial clearance and treatment failure. Bacteriophages have, over the decades, been proved to play an important role in combating bacterial infections (phage therapy), making them an important alternative to classical antibiotic strategies today. Phages have been found to be effective at killing various species of extracellular bacteria, but little is still known about how phages control intracellular infections. With advances in phage genomics and mechanisms of delivery and cell uptake, the development of phagebased antibacterial strategies to address the treatment of intracellular bacteria has general potential. In this review, we present the current state of knowledge regarding the application of bacteriophages against intracellular bacteria. We cover phage deployment against the most common intracellular pathogens with special attention to therapeutic and preventive strategies.

show abstract

“…(3) Gastrointestinal delivery (Tanji et al, 2005;Capparelli et al, 2006;Raya et al, 2006;Sheng et al, 2006;Niu et al, 2008;Rozema et al, 2009;Bach et al, 2009;Jamalludeen et al, 2009;Mai et al, 2010;Stanford et al, 2010;Maura et al, 2012;Jaiswal et al, 2013;Abdulamir et al, 2014;Jaiswal et al, 2014;Jun et al, 2014;Mai et al, 2015;Nale et al, 2015;Sarker et al, 2016;Nikkhahi et al, 2017;Yen et al, 2017;Zhao et al, 2017;Vahedi et al, 2018;Bhandare et al, 2019;Dallal et al, 2019;Dissanayake et al, 2019;Xue et al, 2020) 26 ( 36) (Sarker et al, 2017;Corbellino et al, 2019)…”

Section: (17)unclassified

Phage Therapy: The Pharmacology of Antibacterial Viruses

Danis-Wlodarczyk¹,

Dąbrowska²,

Abedon³

2021

Current Issues in Molecular Biology

View full text Add to dashboard Cite

Pharmacology can be differentiated into two key aspects, pharmacodynamics and pharmacokinetics. Pharmacodynamics describes a drug's impact on the body while pharmacokinetics describes the body's impact on a drug. Another way of understanding these terms is that pharmacodynamics is a description of both the positive and negative consequences of drugs attaining certain concentrations in the body while pharmacokinetics is concerned with our ability to reach and then sustain those concentrations. Unlike the drugs for which these concepts were developed, including antibiotics, the bacteriophages (or 'phages') that we consider here are not chemotherapeutics but instead are the viruses of bacteria. Here we review the pharmacology of these viruses, particularly as they can be employed to combat bacterial infections (phage therapy). Overall, an improved pharmacological understanding of phage therapy should allow for more informed development of phages as antibacterial 'drugs', allow for more rational post hoc debugging of phage therapy experiments, and encourage improved design of phage therapy protocols. Contrasting with antibiotics, however, phages as viruses impact individual bacterial cells as single virions rather than as swarms of molecules, and while they are killing bacteria, caister.com/cimb 81 Curr. Issues Mol. Biol. Vol. 40bacteriophages also can amplify phage numbers, in situ. Explorations of phage therapy pharmacology consequently can often be informed as well by basic principles of the ecological interactions between phages and bacteria as by study of the pharmacology of drugs. Bacteriophages in phage therapy thus can display somewhat unique as well as more traditional pharmacological aspects.

show abstract

The Yersinia Phage X1 Administered Orally Efficiently Protects a Murine Chronic Enteritis Model Against Yersinia enterocolitica Infection

Cited by 21 publications

References 42 publications

Genomic, Morphological and Functional Characterization of Virulent Bacteriophage IME-JL8 Targeting Citrobacter freundii

Genomic, Morphological and Functional Characterization of Virulent Bacteriophage IME-JL8 Targeting Citrobacter freundii

Applications of bacteriophages against intracellular bacteria

Phage Therapy: The Pharmacology of Antibacterial Viruses

Contact Info

Product

Resources

About